The global monoclonal antibody therapeutics market size was worth $97.7 bn in 2017 and is expected to reach US$275.8 bn by 2026. Between the forecast years of 2019 and 2026, the overall market is expected to rise at a CAGR of 17.6%.
Monoclonal antibodies are a type of biological therapy used in the treatment serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, psoriasis, osteoporosis, systemic lupus erythematous, and others. Monoclonal antibody are target specific in action by not affect the other cells of the body thus restores the immune system.
The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on application, source, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the market in the current and future scenario.
Segmentation
This report analyzes the current and future prospects of the market based on type of application, source, end user and geography. By application monoclonal antibodies are segmented according to the therapeutic area such as cancer, autoimmune diseases, infection, hematological diseases, ophthalmological diseases and others which include monoclonal antibodies used in treating cardiovascular, respiratory, and orthopedic disorders as well as monoclonal antibodies used in the prevention of transplant rejection.
By source monoclonal antibodies are segmented into human, humanized, chimeric, and others, which include peptide body and murine antibodies. The human monoclonal antibody segment is expected to be highest contributing segment in the monoclonal antibody therapeutic market during the forecast period. Various factors such as patent expiry of block buster drugs, robust pipeline of monoclonal antibodies indicated in the treating various types of cancer and other disorders such as hematological, cardiovascular and orthopedic and upcoming biosimilars, define the market growth over the forecast period.
Research Methodology
The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases.
The report provides estimated market size in terms of US$ Mn for each by application, source, end user, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, annual revenue generated by products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies.
Regional Outlook
Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The study also covers detailed country analysis contributing majorly in the market.
Key Players:
The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the monoclonal antibody therapeutics market are Bayer AG, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline Plc., Merck & Co., Inc., Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, Bristol – Myers Squibb Company and Biogen Inc. .
The monoclonal antibody therapeutics market has been segmented as follows:
By Application
By Source
By End Users
By Geography
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Monoclonal Antibody Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Application Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Product/Application/End Users Specific
4.3.3. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, 2016–2026
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Monoclonal Antibody Therapeutics Market - Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.8. Value Chain Analysis
4.9. Market Outlook
5. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, By Application
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast By Application , 2016–2026
5.4.1. Cancer
5.4.2. Autoimmune diseases
5.4.3. Infection
5.4.4. Hematological diseases
5.4.5. Ophthalmological diseases
5.4.6. Others
5.5. Market Attractiveness By Application
6. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, By Source
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast By Source , 2016–2026
6.4.1. Human
6.4.2. Humanized
6.4.3. Chimeric
6.4.4. Others
6.5. Market Attractiveness By Source
7. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, By End Users
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Forecast By End Users , 2016–2026
7.4.1. Hospital
7.4.2. Private Clinic
7.4.3. Research Institutes
7.5. Market Attractiveness By End Users
8. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Policies and Regulations
8.3. Market Value Forecast By Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Market Attractiveness By Country/Region
9. North America Monoclonal Antibody Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Key Trends
9.2. Market Value Forecast By Application , 2016–2026
9.2.1. Cancer
9.2.2. Autoimmune diseases
9.2.3. Infection
9.2.4. Hematological diseases
9.2.5. Ophthalmological diseases
9.2.6. Others
9.3. Market Value Forecast By Source , 2016–2026
9.3.1. Human
9.3.2. Humanized
9.3.3. Chimeric
9.3.4. Others
9.4. Market Value Forecast By End Users , 2016–2026
9.4.1. Hospital
9.4.2. Private Clinic
9.4.3. Research Institutes
9.5. Market Value Forecast By Country , 2016–2026
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Application
9.6.2. By Source
9.6.3. By End Users
9.6.4. By Country
10. Europe Monoclonal Antibody Therapeutics Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.1.4. Key Trends
10.2.Market Value Forecast By Application , 2016–2026
10.2.1. Cancer
10.2.2. Autoimmune diseases
10.2.3. Infection
10.2.4. Hematological diseases
10.2.5. Ophthalmological diseases
10.2.6. Others
10.3.Market Value Forecast By Source , 2016–2026
10.3.1. Human
10.3.2. Humanized
10.3.3. Chimeric
10.3.4. Others
10.4.Market Value Forecast By End Users , 2016–2026
10.4.1. Hospital
10.4.2. Private Clinic
10.4.3. Research Institutes
10.5.Market Value Forecast By Country , 2016–2026
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6.Market Attractiveness Analysis
10.6.1. By Application
10.6.2. By Source
10.6.3. By End Users
10.6.4. By Country
11. Asia Pacific Monoclonal Antibody Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.1.4. Key Trends
11.2.Market Value Forecast By Application , 2016–2026
11.2.1. Cancer
11.2.2. Autoimmune diseases
11.2.3. Infection
11.2.4. Hematological diseases
11.2.5. Ophthalmological diseases
11.2.6. Others
11.3.Market Value Forecast By Source , 2016–2026
11.3.1. Human
11.3.2. Humanized
11.3.3. Chimeric
11.3.4. Others
11.4.Market Value Forecast By End Users , 2016–2026
11.4.1. Hospital
11.4.2. Private Clinic
11.4.3. Research Institutes
11.5.Market Value Forecast By Country , 2016–2026
11.5.1. Japan
11.5.2. China
11.5.3. Australia
11.5.4. New Zealand
11.5.5. India
11.5.6. Rest of Asia Pacific
11.6.Market Attractiveness Analysis
11.6.1. By Application
11.6.2. By Source
11.6.3. By End Users
11.6.4. By Country
12. Latin America Monoclonal Antibody Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.1.4. Key Trends
12.2.Market Value Forecast By Application , 2016–2026
12.2.1. Cancer
12.2.2. Autoimmune diseases
12.2.3. Infection
12.2.4. Hematological diseases
12.2.5. Ophthalmological diseases
12.2.6. Others
12.3.Market Value Forecast By Source , 2016–2026
12.3.1. Human
12.3.2. Humanized
12.3.3. Chimeric
12.3.4. Others
12.4.Market Value Forecast By End Users , 2016–2026
12.4.1. Hospital
12.4.2. Private Clinic
12.4.3. Research Institutes
12.5.Market Value Forecast By Country , 2016–2026
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6.Market Attractiveness Analysis
12.6.1. By Application
12.6.2. By Source
12.6.3. By End Users
12.6.4. By Country
13. Middle East & Africa Monoclonal Antibody Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.1.4. Key Trends
13.2.Market Value Forecast By Application , 2016–2026
13.2.1. Cancer
13.2.2. Autoimmune diseases
13.2.3. Infection
13.2.4. Hematological diseases
13.2.5. Ophthalmological diseases
13.2.6. Others
13.3.Market Value Forecast By Source , 2016–2026
13.3.1. Human
13.3.2. Humanized
13.3.3. Chimeric
13.3.4. Others
13.4.Market Value Forecast By End Users , 2016–2026
13.4.1. Hospital
13.4.2. Private Clinic
13.4.3. Research Institutes
13.5.Market Value Forecast By Country , 2016–2026
13.5.1. South Africa
13.5.2. UAE
13.5.3. Saudi Arabia
13.5.4. Rest of Middle East and Africa
13.6.Market Attractiveness Analysis
13.6.1. By Application
13.6.2. By Source
13.6.3. By End Users
13.6.4. By Country
14. Competition Landscape
14.1.Market Player – Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2015)
14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. Bayer AG
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. F. Hoffmann-La Roche Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Sanofi
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. GlaxoSmithKline plc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Merck & Co., Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Novartis AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. AbbVie Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Amgen Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Johnson & Johnson
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Bristol-Myers Squibb Company
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Biogen Inc.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Financial Overview
14.3.12.3. Product Portfolio
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers